Señales en vivo de ADXN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 16:00):

Stats
Volumen de hoy	63 362.00
Volumen promedio	18 803.00
Capitalización de mercado	22.06M
EPS	$0 ( 2024-04-04 )
Próxima fecha de ganancias	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.420
ATR14	$0.0820 (1.03%)

Volumen Correlación

Largo: -0.05 (neutral)

Corto: -0.07 (neutral)

Signal:(45.847) Neutral

Addex Therapeutics Ltd Correlación

10 Correlaciones Más Positivas
SVAC	0.974
CVGI	0.957
CYN	0.956
MESA	0.955
DARE	0.954
WISA	0.954
MCRB	0.952
UCTT	0.952
CFRX	0.952
CURI	0.952

10 Correlaciones Más Negativas
NETE	-0.974
LDHA	-0.965
VLAT	-0.964
HORI	-0.964
LGAC	-0.96
MSDAU	-0.96
ABGI	-0.96
HCNE	-0.96
HERAU	-0.959
CRZN	-0.959

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Addex Therapeutics Ltd Correlación - Moneda/Commodity

-0.48
( neutral )

-0.61
( weak negative )

-0.44
( neutral )

-0.62
( weak negative )

0.81
( strong )

0.47
( neutral )

Addex Therapeutics Ltd Finanzas

Annual	2023
Ingresos:	$1.61M
Beneficio Bruto:	$-5.32M (-329.99 %)
EPS:	$-0.140

FY	2023
Ingresos:	$1.61M
Beneficio Bruto:	$-5.32M (-329.99 %)
EPS:	$-0.140

FY	2022
Ingresos:	$1.42M
Beneficio Bruto:	$-13.20M (-928.06 %)
EPS:	$-0.460

FY	2021
Ingresos:	$2.92M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.70

Financial Reports:

No articles found.

Addex Therapeutics Ltd

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.